Pharmacokinetics of an elevated dosage of micafungin in premature neonates. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

http://www.wikidata.org/entity/Q30436332

about

Innovative clinical trial design for pediatric therapeutics Treatment and prophylaxis of invasive candidiasis Neonatal candidiasis: diagnosis, prevention, and treatment Advances in the treatment of invasive neonatal candidiasis Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Changes in the incidence of candidiasis in neonatal intensive care units.Safety and pharmacokinetics of repeat-dose micafungin in young infants.Prediction of micafungin area under the curve data by using peak concentration: applicability and utility in antifungal therapy.Micafungin use in children.Population pharmacokinetics of micafungin in neonates and young infants Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Neonatal infectious diseases: evaluation of neonatal sepsis.Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Regulatory science needs for neonates: a call for neonatal community collaboration and innovation Dosing in neonates: special considerations in physiology and trial design.Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin.Population pharmacokinetics of micafungin and its metabolites M1 and M5 in children and adolescents.Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study.Commentary: pediatric antifungal drug development: lessons learned and recommendations for the future.Pharmacokinetics of antifungal agents in children.Short versus long infusion of meropenem in very-low-birth-weight neonates Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience.High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis.Pediatric antifungal agents.Safety of micafungin in infants: insights into optimal dosing.The management of Candida infections in preterm neonates and the role of micafungin.Fungal infections in pediatric intensive care units.Echinocandin use in the neonatal intensive care unit.The use of antifungal therapy in neonatal intensive care.Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.Invasive fungal infections in newborns and current management strategies.Considerations in the pharmacologic treatment and prevention of neonatal sepsis.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients.Update on the management of Candida infections in preterm neonates.Impact of special patient populations on the pharmacokinetics of echinocandins.Pharmacokinetic considerations in treating invasive pediatric fungal infections.

P2860

Q24635308-3E294798-DC75-4E4E-97D5-E92F9719FB3D Q27001567-23DA216B-8477-4A71-90DB-99253ACAED2A Q27008471-67A0DF4B-35E6-45CA-B16F-88581E2E5F84 Q27022585-FDF02167-3370-4B18-96A0-0BC72F642706 Q27025299-D96C24DF-68F0-4BD0-9861-D44767BFA84B Q30408409-00F7B24E-252D-44BE-835F-E44ADBFED59F Q30433612-56EF9D50-069A-441F-80BE-C70D9ED22D13 Q31075176-027CECF9-27D2-4D59-BD76-63857ECB4EA6 Q33397111-B8D926F9-4408-4ACF-9A1C-E0C36D746155 Q33876608-CB833EFB-84F7-475F-9133-2F7A01A77017 Q34212799-E0CD4239-AC67-47F7-BCF6-8A2C976461EC Q34332344-07F25969-DDA8-434E-A91E-360B38F32BB4 Q34337608-BB7F8CEB-0EC1-4FAC-92F2-2B58AEBFAEC5 Q34505582-0C22F89B-4149-4A44-A25A-CC84D34A3ABF Q34593375-8EBCB188-F079-4B0B-B417-02A074B952DA Q34716879-152F4DE2-D92D-40AD-8C9D-DB8193C86694 Q35065859-C670BB90-9515-4AB9-B4CF-01BBD9800DD3 Q35105985-B2BBFCE4-F1C2-400E-B0DF-1A4979E10F30 Q35787372-AB25FBC8-A08E-405B-BD8C-60EB7A76C68B Q35973357-C8A059A7-581E-4BAB-9BD2-D1D31851B742 Q36163345-060D1D34-773C-4A98-B4B5-D36AF253DB7A Q36172523-09AA0BC8-789C-4581-9E5F-FC9F073A21FF Q36276191-956FD094-A2BC-442F-9A68-2A62D7887B65 Q36948094-A5615D55-C771-4077-9ECF-AB8221C95622 Q37203671-4BB87353-CEBA-4F90-8CF3-48483D703FDB Q37428675-6EA07E00-8827-4ED2-8917-7CBDCC213D88 Q37594515-E123ACDA-0728-4D00-8E0C-F84EA4AE80E8 Q37827883-F6438495-3621-4BB6-9F5C-18F7622EDDA3 Q37900293-08F32B5C-5209-41A6-B3B2-F7E11D04581D Q37900308-BF473A40-68A2-46F7-AF91-5DEB5BE71984 Q37970649-BDDB343F-5291-47D0-B510-163F7263CEA8 Q37985070-4B430DF3-514C-4875-B3BD-171902F68DD5 Q38053482-821F64A1-8B58-4AAA-800A-2E748309AC20 Q38119554-3684958E-7D3A-459B-B01B-AD7D44E48A22 Q38161849-76AB01E8-AAC1-4156-9B64-4355FB913983 Q38215682-EC5AA604-7619-4B7C-A744-B492F5317B5B Q38314467-291A33D9-F871-4364-9793-56796C414EC4 Q38326174-51E6CBBC-F314-40CA-A110-86606048161B Q38462784-CD4920B9-1623-442B-9DA9-B234A33E24D3 Q38816614-B1B9811C-C038-45D8-96FF-B7F4122391D9

P2860

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

http://www.wikidata.org/entity/Q30436332

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@ast

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@en

type

label

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@ast

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@en

prefLabel

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@ast

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@en

P1433

Q30436332-E0988680-94A1-4F95-AA91-81BF62E691DA

P1476

Q30436332-ED2EA645-FD84-44F1-996B-841F3886F730

P2093

Q30436332-0ACCB882-811D-4903-802C-FF0E23EAB108

Q30436332-1902E073-CEAA-4B36-81A3-DADE0B690F2C

Q30436332-2370575D-B38E-4057-AD23-6C1FB7222CFF

Q30436332-59BD9F96-A898-48B2-BC57-5320861E2DAB

Q30436332-7D72B13B-3BD9-4B96-8A27-5AF3CDF97FE3

Q30436332-B2274628-6A09-4812-B015-A83BDD312C77

Q30436332-E1AE5C9C-48B0-41DF-9975-14A1BAE7E53E

Q30436332-E2AB4216-3E2B-49F1-BFBD-C0C8F7A8BD6D

Q30436332-E752A9F3-8612-4CCF-91B7-37423DAB87FC

Q30436332-EC4821A8-1101-4B9A-A6F0-C486AE165177

P2860

Q30436332-0F103FF6-AC61-48CA-A113-55BDC0F6FB94

Q30436332-13BD5F8B-353F-4FDF-B8F3-66C232B41C0B

Q30436332-2550C7F5-7F8A-4AE3-A637-30A2020517D6

Q30436332-342B8079-09D6-47E1-AE5C-AF00FC04D049

Q30436332-5D68BB47-E989-4A72-8C10-54A05E1CFF61

Q30436332-6C7B419B-7900-41BB-B0BA-B98CEEE6A291

Q30436332-95DBE906-B0C1-40A4-A14E-4F960E20B18A

Q30436332-A4D50091-31C2-434F-895E-5E51C0273701

Q30436332-B9AC1F7F-A877-49F6-A7B4-CD7AD60F26F7

Q30436332-BE1EE4AB-1EAF-459E-881B-5885632727DA

P304

Q30436332-F180ED3F-D7F5-4EAE-AF5C-3E5F63F761E0

P31

Q30436332-FE5FCDAA-B257-41B0-8CB5-15741926E3B8

P356

Q30436332-3B06FB08-CE50-481E-B6C7-B96358C96A07

P433

Q30436332-3B464BBB-7101-411C-9171-277C76863D39

P478

Q30436332-23B70AD0-6E75-45E2-A4CE-41153D79E065

P50

Q30436332-E6A024A1-D61E-4890-84D2-390A882E5141

P577

Q30436332-FE38A180-9056-475B-8CC3-82ED2531D19A

P698

Q30436332-AACD7FC6-1CB2-4915-90EC-1ACD0B64E485

P921

Q30436332-5FE8D0EA-BC79-4328-BEBB-E17D571B3270

P932

Q30436332-77E63D76-6C2B-475D-8D7E-6B418A19C7BE

P356

INF.0B013E3181910E2D

P1433

Pediatric Infectious Disease Journal

P1476

Pharmacokinetics of an elevated dosage of micafungin in premature neonates.

@en

P2093

Akitsugu Takada

http://www.w3.org/2001/XMLSchema#string

Antonio Arrieta

http://www.w3.org/2001/XMLSchema#string

Daniel K Benjamin

http://www.w3.org/2001/XMLSchema#string

David Kaufman

http://www.w3.org/2001/XMLSchema#string

Donald N Buell

http://www.w3.org/2001/XMLSchema#string

Gregory L Kearns

http://www.w3.org/2001/XMLSchema#string

Laura L Kovanda

http://www.w3.org/2001/XMLSchema#string

P Brian Smith

http://www.w3.org/2001/XMLSchema#string

Taiji Sawamoto

http://www.w3.org/2001/XMLSchema#string

Thomas J Walsh

http://www.w3.org/2001/XMLSchema#string

P2860

Echinocandin antifungal drugs

Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations.

Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.

Population pharmacokinetics of amphotericin B lipid complex in neonates.

Mucocutaneous candidiasis.

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants.

Neonatal invasive candidiasis: a prospective multicenter study of 118 cases.

P304

412-415

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/INF.0B013E3181910E2D

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19319022

http://www.w3.org/2001/XMLSchema#string

P921

pharmacokinetics

P932

2747507

http://www.w3.org/2001/XMLSchema#string